Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC lessened its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,092 shares of the life sciences company’s stock after selling 2,950 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Illumina were worth $1,962,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Brown Brothers Harriman & Co. grew its stake in Illumina by 460.9% during the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after purchasing an additional 106 shares in the last quarter. State of Wyoming acquired a new stake in Illumina during the 2nd quarter valued at approximately $32,000. Penserra Capital Management LLC acquired a new stake in Illumina during the 1st quarter valued at approximately $64,000. ST Germain D J Co. Inc. acquired a new position in shares of Illumina in the 2nd quarter worth approximately $36,000. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Illumina in the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The stock was acquired at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several research reports. StockNews.com upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Barclays lifted their price target on Illumina from $50.00 to $80.00 and gave the company an “underweight” rating in a research report on Thursday, January 25th. Finally, Guggenheim initiated coverage on Illumina in a report on Thursday, December 14th. They set a “buy” rating and a $155.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $166.95.

Illumina Stock Down 1.0 %

Shares of NASDAQ:ILMN traded down $1.36 during midday trading on Thursday, reaching $137.32. The company had a trading volume of 916,873 shares, compared to its average volume of 1,786,282. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average price is $138.39 and its 200 day moving average price is $129.38. The stock has a market cap of $21.82 billion, a PE ratio of -18.71 and a beta of 1.19. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $233.42.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter last year, the company posted $0.14 earnings per share. Illumina’s quarterly revenue was up 3.6% on a year-over-year basis. Research analysts forecast that Illumina, Inc. will post 0.91 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.